An Open Letter to Patients and Their Families from BridgeBio Pharma CEO Neil Kumar

The rapid spread of COVID-19 globally has led to tremendous disruption in the health care industry. We are actively assessing the impact the virus will have on our work at BridgeBio, including the timing of our clinical trials. We are doing our absolute best to minimize any delays, but we know that right now health […]

BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations Ohio State University-Led Trial to Study Infigratinib for Treatment of Patients with Advanced or Metastatic Solid Tumors with FGFR Genetic Alterations SAN FRANCISCO – March 12, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics announced today that patients […]

BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes

PALO ALTO, Calif., March 4, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, […]

BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes

PALO ALTO, Calif. – March 4, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Palo Alto, CA, March 3, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 2, 2020, the compensation committee of BridgeBio’s board of directors granted two new employees options to purchase an aggregate of 5,812 shares of the Company’s common stock with a per […]

BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress

-Achieved multiple clinical and pre-clinical milestones across BridgeBio’s pipeline -Delivered pipeline expansion with addition of five new drug development and discovery programs; BridgeBio’s portfolio now includes more than 20 potential medicines -Ended quarter with $577.1 million in cash, cash equivalents and marketable securities SAN FRANCISCO, March 02, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: […]